CorMedix

The Melinta acquisition provides repeatable, hospital-channel marketed sales that can sustain a much larger revenue base and support operating leverage because those products are already commercial and can be sold through the expanded sales platform. If true, the company can sustain high revenues and convert fixed selling costs into margin expansion; if false, 2025 revenue may prove transient and margins will compress once acquisition effects normalize.

DefenCath's net pricing and therefore a material portion of company revenue and margin are driven by CMS TDAPA/post-TDAPA add-on payments; a lower CMS-calculated add-on will materially reduce net pricing and revenues even if utilization stays constant. If CMS reimbursement falls as expected for H2 2026, reported revenue and margins will decline; if CMS sets a more favorable add-on in 2027, pricing can recover.

The combined business can generate sustained positive operating cash flow because 2025 shows a large operating cash flow swing driven by acquired product sales and initial integration — enabling self-funded operations and reduction of leverage. If operating cash flow remains positive, CorMedix can fund contingent payments, service convertible notes, and invest organically without heavy dilution; if cash flow reverts negative, the company may need capital markets access and dilution.

REZZAYO's ongoing Phase III prophylaxis study (expected to complete in 2026) is a material organic growth lever: a positive readout and subsequent labeling expansion for prophylaxis would expand hospital use and materially increase REZZAYO net sales. If REZZAYO gains a prophylaxis indication, CorMedix would add a higher‑value, hospital prophylaxis market and accelerate revenue growth; if the trial fails or is delayed, one of the chief pipeline growth catalysts disappears.